Baxter uses cell separation technology, enters stem cell field

04/18/2007 | Reuters

Best known for IV drips, Baxter International, has quietly entered the $1 billion potential market of stem cell research with a trial making use of its cell separation technology. The trial uses autologous stem cell therapy, which involves harvesting stem cells from the patient's own bone marrow, to repair oxygen-deprived heart tissue. The drug G-CSF is administered to stimulate the bone marrow to produce more stem cells.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC